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Abstract description: Cancer is a disease that has killed millions and cost trillions. It
is a tragic disease, and while the treatment used may help fight cancer, potential
long-lasting damage is inflicted onto the heart. Chemotherapies are widespread
drugs used to treat any and all kinds of cancer. There are many different classes
including, but not limited to, the anthracyclines, taxanes, monoclonal antibodies,
alkylating agents, tyrosine kinases, and antiestrogens. For patients with breast
cancer, there are about 69 different chemotherapies approved for treatment, and
they are all from a variety of different classes. However, most of the classes of
chemotherapies are associated with some kind of cardiotoxicity. The anthracyclines
are associated with Type 1 cardiotoxicity, meaning that the damage induced on the
heart is irreversible and often leads to heart failure. The monoclonal antibodies are
associated with Type 2 cardiotoxicity, meaning that the damage induced is typically
reversible and that it is not dose dependent. This kind of damage is typically
repaired upon completion of chemotherapy treatment and possibly going on heart
medications. With that being said, depending on the specific chemotherapy used, it
can be given in a situation where a type 2 chemotherapy induces type 1 effects, such
that a monoclonal antibody is given with or too soon after anthracycline treatment.
The goal of this thesis is to examine one of each of the above classes of
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chemotherapeutic drugs. The mechanism of action and the effects on the heart are
discussed in detail.
Keywords and phrases: chemotherapy, cardiotoxicity, anthracyclines, dexrazoxane,
taxanes, monoclonal antibodies, alkylating agents, tyrosine kinases, antiestrogens
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Table 1
Chemotherapy Drug Details
Chemotherapy

Side Effects

Class

Method
of
Dosage

How
often?

Lapatinib
(Tykerb)

Liver damage,
shortness of
breath,
heartburn,
fast or
irregular
heart beat

Kinase
Inhibitors

Oral

1/day

Trastuzumab

Heartburn,
Short of Air,
Fast/irregular
heart beat

Monoclonal
antibodies

Liquid IV

1/week

Cyclophosphamide

Difficulty
breathing,
SOB, chest
pain

Alkylating
agents

Injected
Powder

Depends

Docetaxel

Extreme
tiredness,
stomach pain

Taxanes

Liquid IV

3 weeks

Doxorubicin
Hydrochloride

Heart
problems

Anthracyclines

Liquid IV

1x every
21-28
days

Tamoxifen Citrate

Coughing up
blood, SOB

Antiestrogens

Oral

Twice a
day
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According to the World Health Organization, cancer killed 9.6 million people
worldwide in 2018, and in 2010, the total cost of cancer was around 1.16 trillion
dollars (2018). Cancer is a disease that is characterized by cells continually dividing
in the body without control. Chemotherapies are drugs used to disrupt this process
and restart the body’s normal process of creating cells as needed and killing those
cells that are damaged and/or are old. The primary objective of chemotherapy is to
“impair mitotic and metabolic process of cancer cells”; however, these drugs are so
potent, that they do not only destroy those cells, but healthy cells, as well
(Angsutararux, Luanpitpong, and Issaragrisil, 2015). Chemotherapies are an
essential part of the treatment for cancer, and although it saves many people from
the horrible fate of cancer, it has its known side effects that can cause many longstanding issues alone.
Within the last 50 years, there have been many studies performed on those
who have had chemotherapies in their past. It is now known that although these

2
drugs are wonderful for the treatment of cancer, it is detrimental to heart function.
According to the National Cancer Institute, the toxic effects on the heart, known as
cardiotoxicity, were first identified in the 1960s. The different types of
cardiotoxicity identified were acute, subacute, and chronic (Mihalcea, Florescu, &
Vinereanu, 2017). Acute cardiotoxicity is toxicity that occurs within 2 weeks of
starting the treatment while subacute cardiotoxicity occurs after 2 weeks of starting
the treatment (Mihalcea, Florescu, & Vinereanu, 2017). Chronic cardiotoxicity
occurs either within 1 year or after 1 year, which typically leads to heart failure and
death (Mihalcea, Florescu, & Vinereanu, 2017).
Depending on the type of chemotherapy and the duration of treatment, the
effects on the heart are widely varied. For example, some classes of chemotherapy
may cause a temporary irregular heartbeat whereas other therapies may lead to
myocyte vacuole degeneration, which is injury to the cardiac muscle cells.
(Angsutararux, Luanpitpong, and Issaragrisil, 2015). Because it is known that
chemotherapies do have an effect on the heart, there have been multiple studies
performed to determine how to treat and/or prevent chemotherapy-induced
cardiotoxicity. Those who fight the long battle of cancer deserve a better treatment
option that is not only effective in fighting cancer, but also comes without the
lifelong and potentially irreversible damage to the heart.
Cancer is a disease, and like any other disease, there are multiple drugs that
can attempt to rid the body of the destructive cells. There are different classes of
chemotherapies ranging from the anthracyclines to the monoclonal antibodies.
Because there are so many different classes and specific drugs approved for the use
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of all cancers, only those that are approved for the use of breast cancer will be
considered. According to the World Health Organization, breast cancer tied with
lung cancer for the number of cases in 2018, which was 2.09 million each
worldwide; moreover, breast cancer is also in the top 5 for cancer deaths at 627,000
deaths in the world (2018). According to the National Cancer Institute, there are
about 69 chemotherapies that have been approved to treat those with breast cancer,
and many of those are in different chemotherapy classes, meaning that the drugs
have different mechanisms of actions and levels of potency (2019). There are many
different types of breast cancer, with one of those being HER2-positive breast
cancer. This kind of breast cancer has a protein known as human epidermal growth
factor receptor 2 (HER2) that fosters the growth of cancer cells; furthermore, these
kinds of cancers are inclined to be more aggressive than any other type of breast
cancer (Mayo Clinic, 2020). Some other types of breast cancer include
angiosarcomas, which is less than 1% of breast cancers; inflammatory breast cancer,
which is between 1-5% of breast cancers; and triple-negative breast cancer, which is
about 15% of breast cancers (American Cancer Society, 2019). The chemotherapy
classes that will be discussed include anthracyclines, monoclonal antibodies,
taxanes, alkylating agents, and kinase inhibitors. For each of the classes of common
chemotherapies, the mechanism of action in the body, and its toxic effects on the
heart will be discussed.
When discussing cardiotoxicity, the classes and individual drugs are divided
into Type I and Type II chemotherapies. Type I chemotherapies are those drugs that
predominantly cause irreversible damage due to cell loss resulting in
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pathophysiology, or injury, of the heart; however, Type II chemotherapies are those
drugs that predominantly cause reversible damage due to alterations in the
mitochondria and proteins in the heart (Curigliano, et al., 2012). With Type II
chemotherapies, often patients can return to normal cardiovascular function with
time; whereas, Type I chemotherapies can induce progressive cardiovascular
disease (Curigliano, et al., 2012). These classifications are based on what generally
occurs with the use of the specific chemotherapy. However, there are exceptions
where a drug may be classified as Type II chemotherapy but when presented in the
right circumstances can trigger Type I-like effects. The severity of the cardiotoxicity
is also determined by the route of administration of the chemotherapy, the dosage
course, and the duration of the treatment (Angsutararux, Luanpitpong, and
Issaragrisil, 2015). As seen in Table 1, all of the drugs in the classes discussed in this
paper can cause some serious side effects; however, not all of them are associated
with the cardiotoxic effects in which some of the classes are known. The differences
in these chemotherapies (their mechanisms and effects) and their classes will be
examined in the entirety of this paper.

Anthracyclines
The class of chemotherapies known as the anthracyclines is very widely used
for many different malignancies, but is most often used to treat breast cancer.
Doxorubicin is a first-line treatment and is used to treat 32% of those with breast
cancer (McGowan et al., 2017). However, the anthracyclines as a whole are
considered to be a Type I chemotherapy and are considered to give rise to heart
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defects that are more common and detrimental than other chemotherapy classes
(Angsutararux, Luanpitpong, and Issaragrisil, 2015). Because of the wide range of
effects that the anthracyclines can impose, the effects are divided into acute and
chronic. Acute effects are those that occur directly after or during the course of the
treatment and are typically reversible; whereas, the chronic effects are those that
can occur years after the treatment and are frequently more detrimental to the
heart (Angsutararux, Luanpitpong, and Issaragrisil, 2015). Risk factors in
developing cardiotoxicity following anthracycline treatment include age (those
younger than 18 and older than 65 are at a greater risk), pre-existing conditions,
and renal failure; hence, those that have a greater number of risk factors, have an
even greater chance of developing congestive heart failure following treatment
(Zamorano, et al., 2016).
The anthracyclines are drugs that target the Topoisomerase-alpha enzyme in
cancer cells that exhibit an extreme division cycle (Tadic, Cuspidi, Hering, Venneri, &
Danylenko, 2017). In a healthy cell, the topoisomerases produce protective effects
on the cell. Topoisomerase-2𝛽 is found largely in cardiomyocytes, cells making up
the heart muscle, thus causing damage to the heart when harmed. However,
doxorubicin binds to the Topoisomerase-2𝛽 enzyme and lowers its ability to protect
against DNA replication normally (Swiger, Singh, & Lenihan 2017). Topoisomerase𝛼 is structurally identical to Topoisomerase-2𝛽, so anthracyclines affect both
leading to anthracycline-induced cardiomyopathy (Tadic, Cuspidi, Vasic, & Kerkhof,
2018). This isoenzyme, Topoisomerase-𝛼, binds to doxorubicin and triggers
mitochondrial dysfunction (McGowan et al., 2017).
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During mitochondrial DNA recombination, Topoisomerase-2𝛽 controls the
chromatin relaxation and condension, while also promoting the rearrangement of
genes (Goffart, Hangas, & Pohjoismäki, 2019). The mitochondrial DNA in mammals
is usually in the shape of a circle, but can be relaxed or coiled tightly; nevertheless,
the mitochondrial DNA in cardiomyocytes are much more complex in that they form
networks with other mitochondria (Goffart, Hangas, & Pohjoismäki, 2019). Because
of this, Topoisomerase-2𝛽, as well as other subunits of topoisomerase, is needed to
relax the coiling during the DNA replication and transcription (Goffart, Hangas, &
Pohjoismäki, 2019). Anthracyclines inhibit Topoisomerase-2𝛽 causing the DNA to
stay coiled tightly; similarly, there has also been evidence of changes in the
structure of mitochondrial DNA attributable to the breaks in the double strands of
DNA that presents with topoisomerase poisoning (Goffart, Hangas, & Pohjoismäki,
2019).
The mitochondria in cardiomyocytes generate reactive oxygen species
through the electron transport chain (Siasos et al., 2018). Doxorubicin-induced
cardiotoxicity may be caused by a multitude of effects including damage to the
mitochondria, apoptosis, and an increase in oxidative stress (Potočnik, et al., 2017).
Anthracyclines in general are known to invoke intracellular damage due to the
production of hydroxyl radicals that are tremendously toxic to the body;
correspondingly, these are made by the production of highly reactive oxygen species
(oxygen species reacting with iron), which are exacerbated with anthracycline
treatment (Tadic, Cuspidi, Vasic, & Kerkhof, 2018). This oxygen species leads to an
increase in apoptosis and deterioration. Anthracyclines, in general, evoke harm on
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the mitochondria and Topoisomerase-2𝛽, which leads to a plethora of other damage
and can ultimately lead to heart failure.
The peroxisome proliferator-activated receptor (PPAR) regulates oxidative
metabolism, which also occurs in the mitochondria (McGowan et al., 2017). This
receptor is activated by a ligand binding to the active site, causing the receptor to
undergo a conformational change that ultimately regulates gene transcription (Lee
& Kim, 2015). The receptor is found in 3 different subtypes in the body: alpha,
gamma, and beta (Tyagi, et al., 2011). The alpha, 𝛼, subunit allows for energy to be
generated for the heart muscle and other areas of the body in playing a crucial role
in the breakdown of fatty acid molecules in the liver (Tyagi, et al., 2011). The
gamma, 𝛾, subunit acts as a receptor and regulates fatty acid storage (Tyagi, et al.,
2011). A study using PPAR-gamma knockout mice, which “exhibit progressive
cardiac fibrosis with abnormal mitochondria and myofibrils,” has demonstrated that
this isoform of PPAR is crucial in the protection of cardiomyocytes (Lee & Kim,
2015). Lastly, the beta, 𝛽, subunit, promotes fatty acid metabolism; however, it has
also been demonstrated that the ligand could potentially inhibit cardiac
hypertrophy (Tyagi, et al., 2011). One study of cardiomyocytes taken from mice
showed that doxorubicin significantly decreased the amount of the PPAR-beta
receptor. As PPAR is protective, cells that exhibit a decrease in receptor number
will lose the ability to effectively protect against cardiac hypertrophy as the cells
have become desensitized (Chen, Chen, & Cheng, 2013). Having too much or too
little of the PPAR, however, could potentially foster cardiomyopathy or further
myocardial damage (Lee & Kim, 2015).
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Anthracyclines are transformed from a quinone form to a semiquinone form
(one electron reduction form) by enzymes in the mitochondria (Angsutararux,
Luanpitpong, & Issaragrisil, 2015). Furthermore, the formation of the semiquinone
form of the anthracycline (in the body) reacts promptly when in contact with
oxygen; likewise, when it reacts with the oxygen, a superoxide anion is formed along
with a hydrogen peroxide, which then leads to an increase in the number of reactive
oxygen species (Edwardson. et al., 2015). As discussed previously, an increase in the
number of reactive oxygen species would increase the rate of apoptosis in cells
(Siasos et al., 2018). This process has been discovered to occur in the mitochondria,
cytoplasm, and sarcoplasmic reticulum and create toxic aldehydes that escape the
cells (Edwardson, et al., 2015). For the heart, however, the semiquinone form of the
anthracycline is more associated with the dysfunction that the form induces to the
mitochondria; moreover, the heart needs adenosine triphosphate (ATP) to pump
blood throughout the body and any damage to the mitochondria would impair that
process (Edwardson, et al., 2015). According to Edwardson, D.W., cardiomyocytes
acquire about 90% of their ATP from the mitochondria (2015). The formation of the
semiquinone form of an anthracycline inducing damage on the mitochondria in
cardiomyocytes reduces the ATP that is formed and ultimately impairs the heart’s
ability to pump blood throughout the body.
Anthracyclines can also go through the reduction of two electrons when in
the body, and the product, secondary alcohol metabolites, have been suggested to be
a potential factor in cardiotoxicity induced by anthracyclines (Edwardson, et al.,
2015). However, the products (hydroxylated anthracyclines) only inflict a greater
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amount of cardiotoxicity than the parent compounds due to their ability to collect in
the tissue of the heart; moreover, the products collect a significant amount more in
the heart than anywhere else in the body (Edwardson, et al., 2015). The reasoning
behind why the products accumulate more in the heart is unknown (Edwardson, et
al., 2015). However, the consequence of hydroxylated anthracyclines building up in
the heart is the onset of cardiomyopathy; furthermore, this could occur at any time
between the beginning of the treatment to months later (Edwardson, et al., 2015).
Doxorubicin is an especially prevalent and effective anthracycline that is
used to treat a variety of different cancers. However, the drug is known for its
extremely damaging effects on the heart. According to Angsutararux, Luanpitpong,
and Issaragrisil, the cumulative amount of doxorubicin that is given is crucial to the
likelihood of succumbing to heart failure following treatment, as exceeding
550𝑚𝑔/𝑚) considerably increases the chances of ending up with congestive heart
failure from 4% to 18% (2015). Similarly, the risk jumps up to a 48% chance when
receiving 700𝑚𝑔/𝑚) (Zamorano, et al., 2016).
Moreover, one study demonstrated that the use of doxorubicin over a 6-week
time frame almost completely rids the body of cardiac-resident stem and progenitor
cells in the myocardium, both of which are stem cells that commit to becoming
cardiomyocytes (Madonna, et al., 2017). Doxorubicin and other anthracyclines have
harmful effects on both the cardiomyocytes and the stem cells that commit to
becoming cardiomyocytes. Without these stem cells, the damage becomes
irreversible and no new cells can be produced.
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Monoclonal Antibodies
Monoclonal antibodies are another class of chemotherapies that is widely
used in the treatment of many cancers, including breast cancer. These immune
system proteins are made in the lab to act like the body’s antibodies and
acknowledge specific targets (National Cancer Institute, 2019). The proteins can
only bind to one substance each, with one of those being cancer cells (National
Cancer Institute, 2019). Monoclonal antibodies can be used alone or with other
chemotherapeutic agents in order to carry substances directly to the cancer cells
(National Cancer Institute, 2019). Some monoclonal antibodies target the immune
system, turning it against the cancer cells, while also binding to the cancer cells in
order to help the immune system kill the cancer cells (National Cancer Institute,
2019). Monoclonal antibodies were not originally meant for chronic therapy, but
later on more human-like monoclonal antibodies were developed (Shepard, et al.,
2017).
Monoclonal antibodies are Type 2 chemotherapies because the effects on the
heart are not dose-dependent and the damage they can cause to the heart is
normally reversible (Tadic, Cuspidi, Hering, Venneri, & Danylenko, 2017). However,
monoclonal antibodies can contribute to the progression of a tumor similar to other
immunosuppressant drugs and cause cardiotoxicity (Singh, et al., 2018). The first
monoclonal antibody was approved by the FDA for cancer treatment (specifically
lowgrade B cell lymphoma) in 1997; likewise, there are now over 60 different
monoclonal antibodies that the FDA has approved (Singh, et al., 2018).
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A common monoclonal antibody used in the treatment of breast cancer is
trastuzumab (Tadic, Cuspidi, Vasic, & Kerkhof, 2018). The tyrosine-protein kinase
expressed on cancer cells is inhibited by trastuzumab; however, cardiomyocytes
express the same kinase and when inhibited, dilated cardiomyopathy is evoked,
which is blood pumping less effectively through the heart due to the expansion, or
dilation, of the left ventricle (Tadic, Cuspidi, Vasic, & Kerkhof, 2018). The human
epidermal growth factor receptor type 2 that trastuzumab inhibits, regulates growth
and survival of cardiomyocytes and other cells (Higgins, O’Halloran, & Chang, 2015).
The chemotherapy has also been linked to the inhibition of the neuregulin-1, which
normally activates the human epidermal growth factor receptor type 2 on
cardiomyocytes as a protective mechanism (Nicolazzi, et al., 2018). This inhibition,
though, causes the inability of the cardiomyocyte to maintain sarcomeres (allows
the lower chambers of the heart muscle to contract in unison and the upper
chambers of the heart to contract in unison) and subproducts of ATP formation.
Moreover, this leads to oxidative stress and the upregulation of angiotensin II, which
prevents neuregulin-1 from binding to other receptors to make up for the blockage
of the human epidermal growth factor receptor type 2 and also induces apoptosis
(Nicolazzi, et al., 2018). This, in turn, leads to greater oxidative stress. Trastuzumab
blocks all of the possible ways for the cardiomyocytes to repair themselves and
regulate their survival, therefore, damaging the heart (but not to the point of no
return). After discontinuing treatment, the heart will be able to work back up to
regulating the cardiomyocytes and the sarcomeres and making any repairs that will
need to be made to the heart.
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Because this kinase receptor regulates survival of the cardiomyocytes, when
it is inhibited, the cardiomyocytes’ ability to repair itself and respond to stress and
injury are also compromised (Higgins, O’Halloran, & Chang, 2015). According to
Higgins, O’Halloran, and Chang, after discontinuing the chemotherapy, the patients
in a study all recovered, with 16% being spontaneous and 84% being with heart
failure treatment (2015). With that being said, if trastuzumab is given with
anthracycline treatment or given too soon after anthracycline treatment, the
damage can become permanent, making it, in this instance, a type 1 chemotherapy
that can lead to the development of congestive heart failure (Higgins, O’Halloran, &
Chang, 2015). Because trastuzumab prevents the heart from repairing itself, the
cardiomyocytes will not be able to repair some of the damage induced by the
anthracyclines if it is introduced too soon after anthracycline treatment. The
damage induced by the anthracyclines will then be built on by the “reversible”
damage of trastuzumab; however, with damage already being done, the
trastuzumab damage will become permanent. Other factors that will put patients at
an increased risk of cardiotoxicity include smoking, diabetes, hypertension, age
(older than 49 years old), a decreased left ventricular ejection fraction, or any
preexisting cardiac diseases (Higgins, O’Halloran, & Chang, 2015).
In patients treated only with trastuzumab, and not anthracyclines before or
during trastuzumab treatment, the incident of cardiomyopathy is much lower;
furthermore, there is no difference in the thickness of the right and left ventricle
walls in a study on mice who were only treated with trastuzumab (Tadic, Cuspidi,
Hering, Venneri, & Danylenko, 2017). This suggests that treatment with
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trastuzumab, when used to treat cancer, prevents the changes that anthracyclines
typically induce and has some cardioprotective effects while also fighting the cancer
cells; however, it can cause some reversible damage of its own. Trastuzumabinduced left-ventricular contractile dysfunction occurs at a rate of around 3% when
given without other chemotherapies (most common); whereas, the risk of heart
failure to patients treated with trastuzumab according to a study of 11,000 patients
was 2.5% (Higgins, O’Halloran, & Chang, 2015). Trastuzumab in breast cancer has
led to a 50% decrease in the cancer returning and has also improved the survival
rate to 33% of those treated with trastuzumab (Curigliano, et al., 2012). In an 11year study of patients treated with trastuzumab after another chemotherapy
(anthracyclines and/or taxanes) in the treatment of breast cancer, the observation
group had 63% of patients with 10 years free of disease; however, there was 69% of
patients with 10-year survival and no diseases for both the group treated with 1
year of trastuzumab and 2 years of trastuzumab (Cameron, Piccart-Gebhart, &
Gelber, 2017). Therefore, there is a significant improvement in the disease outcome.
However, in one study, elevation of the right ventricle filling pressure
signified a decrease in the diastolic function of the right ventricle of the heart (Tadic,
Cuspidi, Hering, Venneri, & Danylenko, 2017). In another study of 9 female breast
cancer patients, it was discovered that after 6 months of trastuzumab therapy, the
circumferential strain on the right ventricle decreased, but the systolic function of
the right ventricle was normal (Tadic, Cuspidi, Hering, Venneri, & Danylenko, 2017).
Circumferential strain is a measure of the reduction of the diameter of the
ventricles, and thus, a measure of cardiac dysfunction (Støylen, 2018). Overall,
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trastuzumab is a safer treatment option for cancers because the damage it induces is
typically reversible, unless it used in combination with anthracyclines, and it has
demonstrated an increase in the survival rate of those with breast cancer.

Taxanes
The taxanes, discovered in the 1960s, are a chemotherapeutic class that is
most often used in the treatment of breast cancer, as it is one of the most effective in
treating the cancer (Gradishar, 2012). It was first used for humans in the 1990s,
specifically for metastatic breast cancer, because in doing clinical trials, there was
hope that it would have improved outcomes in both early and late stage cancer
(Gradishar, 2012). Compared to other chemotherapy regimens, the patient survival
rate when treated with taxanes versus other chemotherapeutic agents is higher;
furthermore, the survival rate of those with metastatic breast cancer between 1991
and 1995 was only 34%, but between 1997 and 2001, the survival rate had
increased to 45% at 2 years (Ho & Mackey, 2014). As of 2016, all of the taxane drugs
are FDA approved to be administered intravenously (Ojima, Lichtenthal, Lee, Wang,
& Wang, 2016).
The taxane chemotherapeutic class promotes both bradyarrhythmias and
tachyarrhythmias, which both can lead to heart failure (Lage, et al., 2019). The
cardiotoxic risks of taking taxanes are not quite known (Zamorano, et al., 2016). It is
known, however, that the taxanes can activate apoptotic pathways (Lage, et al.,
2019). Furthermore, taxanes prevent the mitotic spindle from going through
depolymerization by stabilizing the microtubules 𝛽-tubulin subunit (Lage, et al.,
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2019). This causes cell cycle arrest in both the G2 and Mitosis phases of the cell
cycle, which then causes cell death (Gradishar, 2012). The cell is not able to go
through mitosis because the microtubules are not able to pull the chromosomes to
the opposite side of the cell to go through with cytokinesis, so the cell activates
apoptosis.
Docetaxel is a derivative of paclitaxel (the original taxane discovered in the
1960s) that is more potent (Gradishar, 2012). It was discovered in the 1980s, and
received Food and Drug Administration (FDA) approval in 1996 for the treatment of
breast cancer that has returned for at least the 2nd time (Gradishar, 2012). Docetaxel
is a chemotherapeutic agent that is used in the treatment of many cancers, including
breast cancer and lung cancer. Some toxicities induced by docetaxel include edema
(swelling) and shortness of breath (Ojima, et al., 2016). The chemotherapy often
comes with acute infusion reactions, which means that the symptoms occur within
minutes or hours of receiving the dose of docetaxel; moreover, these symptoms
include fever, hypoxia (low oxygen in the blood), dyspnea (difficulty breathing),
cardiorespiratory arrest and anaphylaxis (Ho & Mackey, 2014).
Docetaxel treatment increases the activity of NADPH oxidases, which is the
source of most of our oxygen production; furthermore, this results in an increase in
reactive oxygen species (Lage, et al., 2019). An increase in the reactive oxygen
species decreases the amount of ATP produced, and then increases the rate of
apoptosis, which ultimately leads to damage of the heart (Siasos et al., 2018).
Heart failure induced by the use of paclitaxel and docetaxel in patients is
anywhere from 2.3-8% of patients (Min & Wierzbicki, 2017). LVEF, left ventricular
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ejection fraction, reductions of at least 15% have presented in 6-8% of patients
(Madeddu, et al., 2016). There have also been cases of myocardial ischemia (blocked
blood flow to the heart) in those treated with either paclitaxel or docetaxel (Min &
Wierzbicki, 2017). Docetaxel stabilizes microtubules, and may therefore, cause
contractile dysfunction; furthermore, left ventricular diastolic dysfunction has been
determined to be induced by docetaxel (Shimoyama, et al., 2001). One of the known
causes of congestive heart failure is diastolic dysfunction (Shimoyama, et al., 2001).
If docetaxel induces left ventricular diastolic dysfunction, the risk of developing
congestive heart failure is going to increase with the use of docetaxel.
A 62-year-old Hispanic man was diagnosed with metastatic prostate cancer
and was being treated with docetaxel (Huq, Balvanz, & Mambourg, 2018). Within 15
minutes of the 2nd cycle of chemotherapy being infused, the patient developed a
stable, but chronic, atrial fibrillation (Huq, Balvanz, & Mambourg, 2018). The patient
abided by the physican’s recommendation of using corticosteroids before the
chemotherapy, but still ended up developing atrial fibrillation (Huq, Balvanz, &
Mambourg, 2018). There is less cardiac toxicity with the use of docetaxel than there
is with paclitaxel, but the risk for heart damage is still there when using docetaxel
because everyone is going to react differently to medications, especially those that
can have very severe side effects, like congestive heart failure. Docetaxel seems to be
better for the treatment of breast cancer compared to the anthracyclines because it
has been demonstrated to increase the survival rate of those with cancer while also
lessening the cardiotoxic effects on the heart; moreover, the drug was first used,
specifically, for the treatment of metastatic breast cancer.
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Alkylating Agents
Alkylating Agents are found both in the environment and in cells, as they are
in pollutants such as tobacco smoke and are also byproducts in the body (Fu, Calvo,
& Samson, 2012). These agents are dangerous to human health because of their
effects, which include cytotoxicity, carcinogenic effects, and teratogenic effects; in
spite of this, the agents are used as a chemotherapy to kill cancer cells (Fu, Calvo, &
Samson, 2012). The alkylating agents are the oldest class of chemotherapies (Han,
Zhou, & Liu, 2017). The United States released mustard gas, an alkylating agent,
against the Germans in World War 2 (1943), which caused a major reduction in the
number of white blood cells; furthermore, this led to the study of them as an
anticancer agent (Iqubal, et al., 2019). They act on cancer cells by adding alkyl
groups to the DNA; thus, the two strands of DNA are then cross-linked and
prevented from replicating (Higgins, O’Halloran, & Chang, 2015). Risk factors
associated with alkylating agents-induced cardiotoxicity include old age,
combination therapy, and total single dose (Han, Zhou, & Liu, 2017).
DNA damage is induced when the alkylating agents react with DNA bases (Fu,
Calvo, & Samson, 2012). When a certain alkylating agent is introduced to the body,
the guanine at the N7-position on DNA, which has a high nucleophilic reactivity, is
typically used to form N7-methyl guanine, a predominant methylation adduct
(Figure 1); moreover, DNA alkylation lesions are formed and N7-methyl guanine is
responsible for 60-80% of them (Fu, Calvo, & Samson, 2012). N7-methyl guanine
itself is not cytotoxic, but it forms apurinic or apyrimidinic (AP) sites, which are
places in the DNA where a purine or pyrimidine is not present on one side of the
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double helix; furthermore, these sites are toxic (Fu, Calvo, & Samson, 2012). These
base adducts can induce mutagenesis and/or inhibit the replication and
transcription of DNA, which leads to cell death in both healthy cells and cancer cells
(Fu, Calvo, & Samson, 2012).
A well-known alkylating agent used in the treatment of many cancers
including lymphoma and breast cancer and autoimmune disorders is
cyclophosphamide. When used in high doses for the treatment of cancer, permanent
damage can be induced due to the heart developing structural injury (Madeddu, C. et
al., 2016). Damage that could be induced includes congestive heart failure,
myocardial depression, and cardiac tamponade, which is a fluid buildup between
the pericardium (the sac surrounding the heart) and the heart muscle (Chakraborty,
Bhattacharjee, & Kamath, 2017). Cardiac tamponade, as well as other damage, puts a
lot of pressure on the heart, making it work harder; therefore, the heart will tire
easier and will be susceptible to heart failure. Out of those who receive a high dose
of cyclophosphamide, 20% has undergone acute cardiac dysfunction (Liu, et al.,
2018). Using cyclophosphamide in high doses is thought to increase the risk of heart
failure anywhere from 7-28% (Madeddu, 2016). This makes cyclophosphamide a
type 1 chemotherapy and dependent upon dose. It is thought that free oxygen
radicals play a role in the cardiotoxicity, but the exact mechanism as to how
cardiotoxicity is induced is not known (Higgins, O’Halloran, & Chang, 2015).
Despite the classification of a type 1 chemotherapy, the odds of long-term
cardiotoxicity induced by cyclophosphamide in a cancer patient are relatively rare
and usually seen when the dosage is over 140 mg/kg before a bone marrow
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transplant (Zamorano, et al., 2016). In 33% of patients undergoing bone marrow
transplantation that were pretreated with cyclophosphamide, there were ECG
changes showing QT prolongation and cardiac arrhythmias (Tamargo, Caballero, &
Delpón, 2015). An ECG detects the electrical activity of the ventricles of the heart as
it pumps blood throughout the body, and each wave is labeled as P, Q, R, S, and T,
respectively. When the heart takes longer to recharge, or refill the ventricles with
blood, it is termed a QT prolongation.
This change in the electrical activity of the heart can lead to arrhythmias. The
use of cyclophosphamide has been linked to many different heart arrhythmias such
as bradycardia, atrioventricular block, atrial fibrillation, supraventricular
tachycardias, and ventricular tachycardia/fibrillation (Zamorano, et al., 2016).
According to Tamargo, Caballero, and Delpón, 7.9-10% of patients administered
with a high dose of cyclophosphamide show atrial and ventricular tachyarrhythmias
24-72 hours after the dose (abnormal rhythms in the upper or lower chambers of
the heart, respectively); however, it disappears spontaneously within a 7-day time
frame (2015). The cardiac manifestation that is most severe and occurs in less than
1-9% of those who used high doses of cyclophosphamide is hemorrhagic necrotic
perimyocarditis (Emadi, Jones, & Brodsky, 2009). A 54-year-old women with normal
heart function was given cyclophosphamide a month before her autologous stem
cell transplantation to mobilize her peripheral blood hematopoietic stem cells, but
within 24 hours after her surgery, she had succumbed to cyclophosphamideinduced cardiotoxicity (Martin, et al., 2017). According to Martin, et al., the autopsy
of the woman’s heart showed moderate hemorrhagic pericarditis and intra-cavity
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thrombus (2017). This is consistent with the clinical presentation of
cyclophosphamide-induced cardiotoxicity, which is congestive heart failure that
occurs suddenly (Martin, et al., 2017). Cardiotoxicity is typically due to left
ventricular function and occurs in 45% of those who undergo bone marrow
transplants (Emadi, Jones, & Brodsky, 2009). Cyclophosphamide has been
connected to apoptosis of the cardiomyocytes and damage of the mitochondria, as
well (Iqubal, et al., 2019). Cyclophosphamide’s metabolites induce the generation of
reactive oxygen species in the mitochondria and cause the inflammation of heart
cells (Iqubal, et al., 2019).
In a study using rat cardiomyocytes, the cells were grown overnight and
exposed to one of the following: cyclophosphamide, 4-hydroxycyclophosphamide,
carboxyethylphosphoramide mustard, or acrolein (Kurauchi, et al., 2017). Moreover,
the cells that were exposed to 4-hydroxycyclophosphamide and acrolein for 24- and
48-hour periods showed myocardial cytotoxicity and higher levels of reactive
oxygen species (produced in the mitochondria) than in the controls (Kurauchi, et al.,
2017). This study manifested the notion that the cyclophosphamide itself was not
cytotoxic, but the metabolites from the cyclophosphamide were causing the damage
to the heart cells (Kurachi, et al., 2017). Acrolein is a metabolite of
cyclophosphamide that is toxic and reactive; therefore, it modifies proteins
substantially and induces myocardial injury (Madeddu, 2016). The 4hydroxycyclophosphamide was converted to acrolein, creating a higher
concentration of it in the cell and an even greater extent of damage to the
cardiomyocytes (Kurachi, et al., 2017).
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Phosphoramide mustard is also formed, which is a neoplastic agent that
causes tumor death; hence, the use in the treatment of cancer (Iqubal, et al., 2019).
As shown in Figure 2, 4-hydro-cyclophosphamide exists with aldophosphamide,
which breaks down into phosphoramide mustard and acrolein in the body;
moreover, the phosphoramide mustard is useful in the treatment of cancer while
the acrolein formed, mentioned above, is toxic to the heart in many ways (Iqubal, et
al., 2019). Acrolein activates caspases by forming an adduct, or bond, with cysteine,
which then causes apoptosis of heart cells (Iqubal, et al., 2019). Acrolein also leads
to oxidative stress making the heart work harder, and thus leading to heart failure,
and potentially death (Iqubal, et al., 2019). As shown in Figure 2, the formation of
acrolein will eventually lead to immune suppression, cardiac inflammation,
endothelial dysfunction and vasoconstriction, or cardiac apoptosis (Iqubal, et al.,
2019).
Cyclophosphamide is a chemotherapy that is also used before transplants;
although this case is rare, it goes to show that even when used in small doses for
transplants, cardiotoxicity could still be an unwanted side effect that can lead to
death. The woman’s heart was healthy going into surgery and all the scans were
normal, but once the cardiotoxicity started, it could not be stopped from killing her.
Cyclophosphamide seems to have a lower risk of irreversible damage to the heart,
and it contains 2 elements of which one is cardiotoxic and the other has anticancer
effects; moreover, research has shown greater promise in making
cyclophosphamide a safer treatment option compared to the anthracyclines that
have to be taken with something else to try to prevent or lessen the cardiotoxic
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effects that are otherwise unavoidable. Cyclophosphamide has different metabolites
that either have anticancer effects or cardiotoxic effects; therefore, creating a
treatment that does not have the cardiotoxic effects of acrolein but has the
anticancer effects of phosphoramide mustard, would be beneficial to many who are
undergoing transplants and to those fighting their battle with cancer.

Tyrosine Kinase Inhibitors
Tyrosine kinases are enzymes that transfer phosphate onto amino acids from
ATP, altering intracellular signaling pathways (Chaar, Kamta, & Ait-Oudhia, 2018).
However, in many cancers, including breast cancer, the enzyme has been found to
be overexpressed, and has led to the development of the Tyrosine Kinase Inhibitors,
or TKIs (Chaar, Kamta, & Ait-Oudhia, 2018). The tyrosine kinase inhibitor binds to
the tyrosine kinase receptor (TKR) preventing the proliferation of cells and
enhancing apoptosis, but as with most chemotherapies, the TKIs have been tied to
cardiotoxicity (Chaar, Kamta, & Ait-Oudhia, 2018). With TKI use, the way that
cardiomyocytes are injured varies depending upon the specific TKI taken (Chaar,
Kamta, & Ait-Oudhia, 2018). Some TKI’s are not as toxic to the heart as others
(Chaar, Kamta, & Ait-Oudhia, 2018). The difference in the mechanisms between the
FDA approved TKIs (greater than 30) that make some toxic to the heart and others
not toxic is still not understood (Brown, Ray, & Herrmann, 2019). Any pre-existing
conditions such as cardiac disease, diabetes, and hypertension, and genetics all
increase the chance of injury to the heart muscle when taking TKIs (Chaar, Kamta, &
Ait-Oudhia, 2018).
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TKIs have been associated with mitochondrial damage due to the inhibition
of kinases that were not targeted, such as protein kinase A; moreover, this can lead
to the hypertrophy of the cardiomyocyte (Chaar, Kamta, & Ait-Oudhia, 2018). QT
prolongation, as mentioned with cyclophosphamide, has also been associated with
TKI use (Chaar, Kamta, & Ait-Oudhia, 2018). Acute vascular events have been tied to
TKI use, which can lead to hypertension and damage to the cardiomyocytes; in spite
of this, not all TKIs induce hypertension (Hermann, et al., 2016).
The TKI lapatinib is a common chemotherapy used in the treatment of breast
cancer. It targets the human epidermal growth factor receptor 2 and the epidermal
growth factor receptor, and it has been speculated that the drug is toxic to the heart
(Choi & Chang, 2017). When compared with other chemotherapies, though, the
lapatinib-induced cardiotoxicity rate was low (Choi & Chang, 2017). The result of
several studies showed no significant increase in the risk for heart issues (Choi &
Chang, 2017). However, patients are still at risk, so there is still careful monitoring
of the heart during the course of treatment (Choi & Chang, 2017). Because the
incidences of those with lapatinib-induced cardiotoxicity are typically reversible
and the risk of cardiotoxicity is low, it is Type II Chemotherapy (Jerusalem,
Lancellotti, & Kim, 2019). The chance of the development of cardiomyopathy in a
patient treated with lapatinib is 1-2% and for heart failure, the chance is 0.1-0.5%;
furthermore, it has the lowest rate of cardiotoxicity (Brown, Ray, & Herrmann,
2019).
Lapatinib has shown to be an effective TKI against triple-negative breast
cancer cells, as it triggers extensive DNA damage (Abo-Zeid, Abo-Elfadl, & Gamal-
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Eldeen, 2019). Triple-negative breast cancer is an aggressive and invasive type of
breast cancer that is difficult to treat (American Cancer Society, 2019). This type
does not have estrogen receptors, progesterone receptors, or a lot of human
epidermal growth factor receptors 2; hence, the name, triple negative (American
Cancer Society, 2019). However, triple-negative breast cancer grows and spreads
faster than other breast cancers while also having limited treatment options and a
worse outcome (American Cancer Society, 2019).
Lapatinib has been thought to be effective as a single agent or in combination
with other chemotherapies for those with breast cancer (Choi & Chang, 2017).
Lapatinib activates the 5’ adenosine monophosphate-activated protein kinase
pathway; furthermore, this pathway inhibits the death of 𝛼-induced
cardiomyocytes, so the therapy may have a cardioprotective effect (Choi & Chang,
2017). When paired with other chemotherapies such as trastuzumab and the
anthracyclines, which induce cardiotoxicity, lapatinib may protect the heart from
some of that damage. There is, however, a chance of developing cardiotoxicity with
the use of lapatinib, but the overall incidence of it in those with breast cancer is low
when compared with trastuzumab (Choi & Chang, 2017).
In a meta-analysis of 45 studies including patients treated with lapatinib,
cardiotoxicity included left ventricular dysfunction and arrhythmias (Choi & Chang,
2017). In the studies, over 600 of the patients in 22 of the studies had cardiac
adverse events and 58 people in 5 of the studies had left ventricular dysfunction
(Choi & Chang, 2017). According to Choi & Chang, overall, 2.70% of those in the
studies had left ventricular dysfunction, arrhythmia, LVEF (left ventricular ejection
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fraction) decrease, and/or other cardiac adverse events (2017). LVEF is, with each
contraction, the amount of blood pumped out of the heart. In a study of patients
with breast cancer, 3.0% of them had cardiotoxicity (Choi & Chang, 2017). The risk
factors associated with lapatinib-induced cardiotoxicity include previous treatment
with anthracyclines, older than 65 years old, a high BMI, previous left ventricular
dysfunction, arterial hypertension, and previous radiation therapy (Zamorano, et al.,
2016). The effects of lapatinib on the heart when used to treat cancer is not fully
comprehended and more research needs to be performed in order to better
understand and verify the mechanisms of action of lapatinib and how it plays into
the role of cardioprotective and cardiotoxic agents.

Antiestrogen
Antiestrogen is another class of chemotherapy that is used in the treatment
of breast cancer. A study using older patients who survived breast cancer from
Taiwan discovered that the use of antiestrogens decreased the risk of developing
lung cancer later on in life (Chu, et al., 2017). Estrogen receptors (alpha and beta)
safeguard the central nervous system and the cardiovascular system; however, they
have also been involved in breast cancer and cardiovascular diseases (Traboulsi, et
al., 2017). These receptors have been found to function in adult cardiomyocytes, and
in a study performed on rats, the destruction of the estrogen receptor alpha
promoted ischemia or reperfusion (Lorga, et al., 2017). Antiestrogens work by
blocking the estrogenic signaling (Traboulsi, et al., 2017). These drugs act as
steroids to compete for the estrogen receptors, and therefore, modify the activity of
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the receptor (Traboulsi, et al., 2017). Antiestrogens compete with estradiol, a form
of estrogen (the female sex hormone), for the estrogen receptor alpha site
(Traboulsi, et al., 2017). In breast cancer cells that tested positive for the estrogen
receptor alpha, there was an increased overall amount of estrogen receptor alpha
due to the increase of the product produced by the ubiquitin-proteasome pathway
(Traboulsi, et al., 2017).
Tamoxifen is a common chemotherapy in the antiestrogen class that is used
to treat breast cancer. Tamoxifen opposes the proliferation of breast cancer cells;
(Traboulsi, et al., 2017). Tamoxifen has been thought to have cardiovascular effects
that are favorable; moreover, these effects include reducing total and low-density
lipoprotein cholesterol levels while increasing the amount of “good” cholesterol,
high-density lipoprotein (Khosrow-Khavar, et al., 2017). In a study comparing
aromatic inhibitors to Tamoxifen, there was a 34% decreased risk of developing
ischemic heart disease when treated with Tamoxifen rather than no treatment;
furthermore, there was a 33% decrease in risk of developing any tamoxifen-induced
cardiovascular events (Khosrow-Khavar, et al., 2017). Likewise, in breast cancer
treatment, there was a 26% decreased risk of myocardial infarction and a 45%
decrease in risk of death due to myocardial infarction (Khosrow-Khavar, et al.,
2017). In a study of women with breast cancer who were either treated with
anthracyclines or with tamoxifen displayed the protective effects that tamoxifen has
on the heart, as the troponin 1 (protein that controls actin and myosin in the heart)
levels stayed the same in the treatment group treated only with tamoxifen and in
the group treated with both anthracycline and tamoxifen; on the other hand, the
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group treated with only anthracyclines had an increase in the levels (Silva, et al.,
2017).

PREVENTIVE STRATEGIES/TREATMENT OPTIONS
With the use of chemotherapies and the knowledge of the cardiotoxicity that
comes with a majority of them, there are some treatment options to help prevent
the cardiotoxicity that is induced. Potential treatments and preventative strategies
include fullenerol, dexrazoxane, carvedilol, troponin, and statins.
Fullenerol has been studied intensely, and a lot of those studies have found
that fullenerol can act as a protective agent to damage induced by the use of
doxorubicin by functioning as a free radical scavenger (Potočnik, et al., 2017).
Furthermore, there is no evidence of it interfering with the anti-cancer activity of
doxorubicin (Potočnik, et al., 2017). In a study on rats with colon cancer, the
development of adenocarcinomas was significantly reduced in the group treated
with just doxorubicin and in the group treated with fullenerol before being treated
with doxorubicin (Potočnik, et al., 2017). Therefore, fullenerol did not have an effect
on doxorubicin treating cancer. Pretreating the rats with fullenerol also kept
oxidation at a normal level, while doxorubicin increases oxidative stress in the heart
(Potočnik, et al., 2017). Furthermore, the ECGs of rats pretreated were normal while
those just treated with doxorubicin show lengthening in the QRS and ST waves
(Potočnik, Perše, Cerar, Injac, & Finderie, 2017). Doxorubicin-induced cardiotoxicity
is prevented by the pretreatment of fullenerol, as it acts as a cardioprotective agent
and resists any changes that doxorubicin tries to induce (Potočnik, et al., 2017).
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Dexrazoxane is an iron-chelating agent that reduces cardiotoxicity induced
by anthracyclines significantly for solid tumors in adults and for leukemia and
Ewing’s sarcoma in children (Curigliano, et al., 2012). Dexrazoxane is also a
Topoisomerase II𝛽 inhibitor, and it is the most studied for protection against
anthracycline-induced cardiotoxicity; furthermore, it does so without inhibiting the
anticancer effects of the anthracycline treatment (Higgins, O’Halloran, & Chang,
2015). The American Society of Clinical Oncology recommends the use of
Dexrazoxane for breast cancer to act as a cardioprotectant against the toxicity
induced by doxorubicin (Curigliano, et al., 2012). Dexrazoxane is only
recommended, though, if the patient has received over 300 mg/𝑚) of doxorubicin
(Higgins, O’Halloran, & Chang, 2015). A meta-analysis of adult patients treated with
anthracyclines demonstrated a reduced risk of heart failure when taking
dexrazoxane (Zamorano, et al., 2016). In children, dexrazoxane was found to protect
the heart without compromising the anticancer effects of chemotherapies; likewise,
in another study, the development of cardiotoxicity in the future was much higher in
those who were not treated with dexrazoxane (Reichardt, et al., 2018). Overall,
dexrazoxane is a promising preventative strategy against the cardiotoxicity that is
induced by chemotherapies, specifically, the anthracyclines and doxorubicin.
Carvedilol is a beta-blocker that has also been thought to prevent any cardiac
damage also induced by doxorubicin (Curigliano, et al., 2012). A study confirmed
that it prevents left ventricular dysfunction and has reduced mortality in those
taking doxorubicin (Curigliano, et al., 2012). Carvedilol has also been shown to
maintain calcium homeostasis, which is vital to the contraction of the heart muscle,
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and decrease oxidative stress (Godishala, Yang, & Asnani, 2018). Beta-blockers have
anti-apoptotic and antioxidant effects, which decrease the damage to the
mitochondria (Godishala, Yang, & Asnani, 2018). In another study performed on
patients with HER2-negative breast cancer showed that there was no cardiotoxicity
or decrease in left ventricular ejection fracture to 35% among the group treated
with carvedilol (Avila, et al., 2018). HER2-negative breast cancer does not have an
excess of the human epidermal growth factor receptor 2 meaning that the cancer
does not respond to chemotherapies that target HER2 (American Cancer Society,
2019). More research on carvedilol is needed to determine if it would be a
preventative strategy that would save cancer patients from cardiotoxicity.
Troponin has been demonstrated to detect chemotherapy-induced
cardiotoxicity long before the drug has had a chance to decrease the left ventricular
ejection fraction (Curigliano, et al., 2012). In patients treated with trastuzumab,
troponin has been determined to distinguish between reversible and irreversible
damage induced; moreover, this is determined by the detection of myocardial cell
necrosis (Curigliano, et al., 2012). The increase of troponin levels demonstrated, in a
study with 114 patients who received a high dose of chemotherapy, a lower
incidence of cardiotoxicity in the future (Zamorano, et al., 2016). Monitoring the
levels of troponin in the body during the chemotherapy treatment may help
determine which patients are at risk for chemotherapy-induced cardiotoxicity in the
future.
Statins are cholesterol medications that decrease the cell’s synthesis of
intrinsic cholesterol and promote the uptake of serum LDL cholesterol, and they
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may be just as potent as other cardiotoxic preventative medications, such as
dexrazoxane (Henninger & Fritz, 2017). There was a stronger cardioprotective
potential in those animals treated with statins than in those treated with carvedilol
(Henninger & Fritz, 2017). They have also shown to decrease oxidative damage;
furthermore, the statins stabilize the mitochondria and decrease the vascular
inflammation (Higgins, O’Halloran, & Chang, 2015). Statins may interfere with
NADPH oxidase, which hinders the toxicity induced by anthracyclines (Henninger &
Fritz, 2017). However, these effects were only studied on acute toxicity, so more
studies are needed for those who develop chronic cardiotoxicity (Henninger & Fritz,
2017). One study performed did demonstrate that statins have the potential to
prevent cardiotoxicity induced by doxorubicin whether the toxicity was acute,
subacute, or chronic (Henninger & Fritz, 2017). Furthermore, a study in 2012 of
breast cancer patients receiving statins during the course of their chemotherapy
displayed a significantly lower risk of heart failure (Henninger & Fritz, 2017).
Statins have also demonstrated their ability to improve the anti-tumor efficiency of
doxorubicin (Henninger &Fritz, 2017). The use of statins during the course of
chemotherapy seems to be cardioprotective and would be great for those enduring
the harsh chemotherapy treatments.

CONCLUSION
Chemotherapies are widely used in the treatment of cancer, and although
they have anticancer effects, the drugs are so potent, that they are also affecting the
heart. There are many classes of chemotherapies and some are more potent than
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others. Anthracyclines are among the most well-known chemotherapies due to the
wide range of cancers they are used to treat, but they also tend to induce
irreversible damage to the heart that ultimately leads to heart failure and death.
Monoclonal antibodies are known for their cardioprotective effects on the heart.
There are many classes of chemotherapies that fall between the anthracyclines and
the monoclonal antibodies on the cardiotoxicity scale. Trastuzumab is among those
drugs that typically cause reversible damage to the heart, unless it’s given in
addition to an anthracycline or given too soon after anthracycline treatment.
Cancer, unfortunately, is a particularly prevalent disease, so the effects of the
treatment used is of utmost importance to those who fight the difficult battle and
come out alive. For someone to survive cancer and chemotherapy only to end up
with chemotherapy-induced cardiotoxicity, that is still losing to cancer. Although,
the person survived cancer the first time around, it is ironic that even then, cancer
still wins because the treatment used is harmful. This brings about the importance
of weighing the risks of all the different chemotherapy options and deciding which
would be best considering the chemotherapy’s ability to kill cancer cells while also
avoiding irreversible damage to the heart. It also puts pressure on drug companies
and scientists to create a drug that is safer than current chemotherapies or
something that can be used to help prevent cardiotoxicity as the chemotherapy is
being used. Cancer has been around for so long, and there is still not a medication
that can treat it without causing other complications. A preventative medication that
has extensive research and has been shown to decrease the cardiotoxic effects that
chemotherapies, and specifically, anthracyclines, have on the heart is dexraxozone.
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Carvedilol, statins, and troponin I are both being researched to prevent and detect
chemotherapy-induced cardiotoxicity. Creating a treatment that is safe and effective
when fighting cancer will improve the lives of many who are able to win their battle
against cancer.
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